Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Contact Us
Contact Us

Transforming
pharmaceutical supply chains

Transforming
pharmaceutical supply chains

Everyone deserves access to life-saving medicines

Current pharmaceutical manufacturing approaches often result in inequitable access to essential medicines. The World Health Organization estimates over two billion people worldwide lack access to basic medicines.

With synthetic biology, we can build more effective solutions to sustainably and responsibly produce medicines and drive more equitable health outcomes around the world.

Our story

Antheia was founded in 2015 out of the Smolke Lab at Stanford University on the premise that yeast could be programmed to efficiently produce complex pharmaceutical ingredients.
Founders Dr. Christina Smolke, CEO and Dr. Kristy Hawkins, CSO collaborated to push the boundaries of synthetic biology, with the steadfast belief this technology and this company will change the world.

  • 2008

    Smolke and Hawkins publish in Nature Chemical Biology on the production of benzylisoquinoline alkaloids in yeast.

  • 2015

    Antheia incorporates and raises Seed financing round. The Smolke Lab also publishes in Science, demonstrating the complete biosynthesis of medical opiates in yeast.

  • 2016

    Antheia receives its first National Science Foundation grant.

  • 2017

    Antheia raises Series A financing and is awarded two grants from the National Institute of Health.

  • 2018

    Antheia receives the Phase II Small Business Innovation Research grant and a second National Science Foundation grant.

  • 2020

    The Smolke Lab publishes in Nature, demonstrating the biosynthesis of medicinal tropane alkaloids in yeast.

  • 2021

    Antheia raises Series B financing.

  • 2023

    Antheia brings its early products to manufacturing scale and continues to develop its pipeline of KSMs and APIs for essential medicines.

Our guiding principles

Antheia strives to be a leader in transparent and transformative essential medicine production. We are guided by a set of value-based beliefs that serve as ethical imperatives in all that we do.

Our guiding principles

Antheia strives to be a leader in transparent and transformative essential medicine production.
We are guided by a set of value-based beliefs that serve as ethical imperatives in all that we do.

Our leadership team

Solving some of the toughest challenges in pharmaceutical manufacturing takes a special team. Antheia’s leadership comprises bright minds and tenacious curiosity, coalesced around a shared vision for the future. We are passionate and relentless in our mission to transform pharmaceutical supply chains.

Board of directors

John Nicols

Patrick Yang, PhD​

Ram Shriram

Kristy Hawkins, PhD

Christina Smolke, PhD

Board of Directors

  • Josh Nicols Antheia Board Member description 4

    John Nicols

  • Patrick Yang, PhD Antheia Board Member description 4

    Patrick Yang, PhD

  • Ram Shriram Antheia Board Member description 4

    Ram Shriram

  • Josh Nicols Antheia Board Member description 4

    Kristy Hawkins, PhD

  • Christina Smolke, PhD Antheia Board Member description 4

    Christina Smolke, PhD

Global Javascript Test

Note to self : here I added the exact same code as the above our story timeline, to confirm if the global Javascript will have individual scrolltriggers per sider
Founders Dr. Christina Smolke, CEO and Dr. Kristy Hawkins, CSO collaborated to push the boundaries of synthetic biology, with the steadfast belief this technology and this company will change the world.

  • 2008

    Smolke and Hawkins publish in Nature Chemical Biology on the production of benzylisoquinoline alkaloids in yeast.

  • 2015

    Antheia incorporates and raises Seed financing round. The Smolke Lab also publishes in Science, demonstrating the complete biosynthesis of medical opiates in yeast.

  • 2016

    Antheia receives its first National Science Foundation grant.

  • 2017

    Antheia raises Series A financing and is awarded two grants from the National Institute of Health.

  • 2018

    Antheia receives the Phase II Small Business Innovation Research grant and a second National Science Foundation grant.

  • 2020

    Smolke Lab publishes in Nature, demonstrating the biosynthesis of medicinal tropane alkaloids in yeast.

  • 2021

    Antheia raises Series B financing.

  • 2023

    Antheia brings its early products to manufacturing scale and continues to develop its pipeline of KSMs and APIs for essential medicines.

Ready to transform pharma?

We are growing fast and looking for talented individuals to be part of our journey.

Join Us

Antheia Secures Second BioMaP-Consortium Project Valued at $12M